click on circles to display study description...
lapatinib plus letrozole (n=642) vs. letrozole (n=644)
randomized controlled trial
lapatinib plus letrozole
lapatinib: PO 1500mg/day / letrozole: PO 2.5mg/day
placebo plus letrozole
letrozole: PO 2.5mg/day
no cross over was permitted at the time of progression
la/mBC - HR-positive - 1st line (L1)
double blind
P3 / PFS at level of 0.05 in HER2 positive population then in the ITT population
Adding lapatinib to letrozole improve significantly PFS for patients with HR-positive breast cancer
lapatinib plus letrozole (n=111) vs. letrozole (n=108)
randomized controlled trial
lapatinib plus letrozole
lapatinib: PO 1500mg/day / letrozole: PO 2.5mg/day
placebo plus letrozole
letrozole: PO 2.5mg/day
no cross over was permitted at the time of progression
la/mBC - HR-positive - 1st line (L1)
double blind
P3 / PFS at level of 0.05 in HER2 positive population then in the total population
powered by vis.js Network